acgood, Thanks for mentioning GSK. You are correct that it was GSK, not Roche, who was partnered with ADLR, and who abandoned Entereg. See table of content regarding study 014. Looks like I forgot the issues with bone fractures on the Entereg arm.
Below is an early response from ADLR and they said the increased cardiovascular issues weren't statistically significant. They did mention the increased incidence of benign and malignancy, but didn't include the statical downplaying. This report wasn't the final word, but GSK did drop Entereg not long afterwards and we haven't heard of Entereg being tested in chronic pain since.
For the record, I thought is was far more likely that Relistor would get approval for label expansion into chronic pain than the chances that Kyprolis from ONXX would get accelerated approval in Multiple Myeloma. It just shows you how "good" my prediction powers are. I am just happy I got one out of two.
Market Data 
Markets 
AI
